Mechanism of bariatric and metabolic surgery: beyond surgeons, gastroenterologists and endocrinologists by Valenti, V. (Víctor) et al.
1130-0108/2020/112/2/229-233 • REVISTA ESPAÑOLA DE ENFERMEDADES DIGESTIVAS 
© Copyright 2020. SEPD y © ARÁN EDICIONES, S.L.
REV ESP ENFERM DIG 2020:112(3):229-233 
DOI: 10.17235/reed.2020.6925/2020
Valentí V, Cienfuegos JA, Becerril S, Frühbeck G. Mechanism of bariatric and meta-
bolic surgery: beyond surgeons, gastroenterologists and endocrinologists. Rev Esp 
Enferm Dig 2020;112(3):229-233
DOI: 10.17235/reed.2020.6925/2020
Mechanism of bariatric and metabolic surgery: beyond surgeons, 
gastroenterologists and endocrinologists
REVIEW
Víctor Valentí1,2,3, Javier A. Cienfuegos1,2, Sara Becerril2,3,4 and Gema Frühbeck2,3,4
1Department of General Surgery. Bariatric and Metabolic Surgery. Clínica Universidad de Navarra. School of medicine. Universidad de Navarra. 
Pamplona, Navarra. Spain. 2CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn). Instituto de Salud Carlos III. Pamplona, Navarra. Spain. 
3Obesity and Adipobiology Group. Instituto de Investigación Sanitaria de Navarra (IdisNA). Pamplona, Navarra. Spain. 4Department of Endocrinology. 
Clinica Universidad de Navarra. School of Medicine. Universidad de Navarra. Pamplona, Navarra. Spain
Received: 31/01/2020 · Accepted: 31/01/2020
Correspondence: Javier A. Cienfuegos. Department of General Surgery. Clínica Universidad de Navarra.
Av. Pío XII, 36. 31008 Pamplona, Navarra. Spain. e-mail: fjacien@unav.es
ABSTRACT
Bariatric-metabolic surgery is the safest, most effective and 
long-lasting treatment for obesity and its associated co-mor-
bidities, whether they be metabolic (type 2 diabetes, hyper-
lipidemia non-alcoholic fatty liver disease) or cardiovascular 
(myocardial infarction, stroke). Due to the obesity pandemic, 
bariatric-metabolic surgery is the second most frequent in-
tra-abdominal procedure and the gastroenterologist and the 
surgeon must be aware of the physiologic changes caused 
by the anatomic reconfiguration following surgery.
Among the mechanisms of action, independent of the loss 
of weight and fat tissue, surgery leads to the release of gut 
hormones related to carbohydrate metabolism (the rapid 
and continuous release of insulin), appetite and degree of 
satiety (glucagon-like peptide 1, peptide Y-Y, grhelin). As a 
result, indications for surgery have been extended to ear-
lier disease stages. Apart from the neurohormonal effects, 
changes in the metabolism of biliary acids and the micro-
biota have also been reported.
The aim of this review is to describe the physiologic chan-
ges caused by bariatric-metabolic surgery.
Keywords: Bariatric surgery. Metabolic surgery. Inflam-
mation. Diabetes type-2. Pathophysiology. Incretins.
INTRODUCTION
Over the last 40 years, one of the most striking changes in 
the human phenotype has occurred with catastrophic re-
percussions on health as a consequence of the progressive 
increased incidence of overweight and obesity in adult and 
child populations (1). According to the World Health Orga-
nization (WHO), in 2015 there were more than 603.7 mi-
llion obese adults and 107.7 million obese children. The 
prevalence of childhood obesity (< 5 years) is estimated to 
be 41 million and continues to increase. In 2013, the Ame-
rican Medical Association (AMA) recognized obesity as a 
medical illness with genetic and epigenetic origins (1). 
In Spain, the prevalence of overweight in adults is estima-
ted to be 39.4 % (46.4 % in males and 32.5 % in females) 
and that of obesity is 22.9 % (22.4 % in males and 21.4 % 
in females (2). The WHO defines obesity as an excessive 
increase in fat accumulation, which leads to pathological 
abnormalities. Obesity is one of the greatest causes of 
risk factors for several chronic diseases, morbidity and 
mortality such as type 2 diabetes mellitus (DM-T2), dys-
lipidemias cardiovascular disease (myocardial infarction, 
stroke), non-alcoholic fatty liver disease (NAFLD), obstruc-
tive sleep apnea (OSA), osteoarthritis, infertility and deve-
lopment of tumors, among others (3,4).
It is worth noting that in obesity, and especially visceral 
obesity, adipose tissue (adipocytes, endothelial cells, fi-
broblast, macrophages) is associated with the release 
of adipokines (adiponectin, leptin, resistin, visfatin) and 
proinflammatory cytokines such as tumor-necrosis factor 
(TNF-α), interleukin-6 (IL-6) and interleukin-12 (IL-12). Fur-
thermore, mediators of clotting such as plaminogen-ac-
tivator inhibitor type 1 (PAI-1), which is related to insulin 
resistance, diabetes, atherosclerosis and cardiovascular 
complications, are also released. However, the impact of 
all these factors is beyond the scope of the present article.
Evidence shows that the systemic “sterile” inflammatory 
response that affects certain tissues (adipose tissue, liver, 
pancreas and heart muscle) is mediated by the stimula-
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tion of the innate immune system by molecular patterns 
associated with tissue damage (DAMPs) (hypoxia, rough 
endoplasmic reticulum stress) (5) (Fig. 1). Hypoxia, cellular 
stress and necrosis promote the activation of macropha-
ges that initiate adipose tissue inflammation. Recently, it 
has been reported that bariatric surgery causes remission 
of the inflammatory response (6).
One of the most novel and promising findings has been the 
relationship between dysbiosis of the microbiota with obe-
sity, DM-T2, and NAFLD. This confirms the participation of 
the immune system (innate and acquired) with metabolic 
disorders (bacterial translocation) (7). Zhang et al. reported 
that Roux-en-Y gastric bypass surgery produced a change 
in the composition of the microbiota in comparison with 
obese subjects (8). Due to limitations of space, we remit the 
reader to a recent review for more detailed information (9).
The most widely accepted parameter to define and clas-
sify overweight and obesity is body mass index (BMI), 
defined as weight in kilograms divided by the square of 
the he ight in meters. A BMI of 25.0-29.9 kg/m2 is consi-
dered as overweight; between 30 to 35 kg/m2, as obesity 
(Class I); 35.0-39.9 kg/m2, morbid obesity (class II); and 
40.0-44.9 kg/m2, super-obesity (Class III).
Other clinical parameters with prognostic value include an in-
crease in waist circumference (≥ 102 cm for males and ≥ 88 cm 
for females), the volume of intra-abdominal visceral fat, thic-
kening of the intima media of the carotid and markers of endo-
thelial dysfunction. All should be included in the assessment 
of an obese patient (3,10). Obesity is of particular interest for 
gastroenterologists and surgeons for several reasons:
1.  Obesity is associated with multiple digestive disorders: 
gastro esophageal reflux (GERD), NAFLD, non-alcoholic 
steatohepatitis (NASH), cirrhosis, hepatocellular carci-
noma, gastric adenocarcinoma, diverticular disease, 
polyps, colon cancer, acute pancreatitis, pancreatic can-
cer and lithiasis (11).
2.  Bariatric-metabolic surgery (BMS) is the safest, most 
effective and long-lasting treatment to reduce over-
weight and fat excess and reverse the comorbidities 
a ssociated with obesity such as DM-T2, hypertension, 
dyslipidemia, atherosclerosis, NAFLD. It also increases 
life expectancy (3,12,13).
3.  BMS is the most frequent intra-abdominal surgical 
procedure after laparoscopic cholecystectomy. It repre-
sents an anatomical and physiologic reconfiguration of 
the digestive tract with adverse effects and complica-
tions. These are both acute and chronic, which require 
the intervention of gastroenterologists (vitamin ma-
labsorption, dumping syndrome, GERD, endoluminal 
stenosis, food intolerance, early satiety, postprandial 
abdominal fullness and bloating). They demand a rapid 
diagnosis and knowledge of the physiological mecha-
nisms of these techniques (3,7,13).
4.  In 2004, bariatric-metabolic endoscopy (BME) was in-
troduced in the multi-disciplinary treatment of obesity, 
and in 2017 more than 14,725 endoluminal procedures 
had been performed (14,15). Similarly, the anatomic re-
modeling caused by surgery poses a challenge for en-
doscopists when such procedures are required.
5.  The gastrointestinal tract is the largest endocrine (ente-
roendocrine cells [EEC]) and immune organ in the body. 
Since the description of secretin by Bayliss and Starling 
in 1902, more than 30 gastrointestinal neuropeptides 
have been identified which regulate appetite, food in-
take and energy balance (16,17).
The aim of this review is to briefly describe the physiologic 
mechanisms induced by BMS in the treatment of obesity 
and DM-T2.
The multiple surgical techniques can be classified into 
three groups: a) restrictive techniques in which the gas-
tric capacity is reduced (examples would be adjustable 
gastric banding [AGB] and vertical tubular gastrectomy 
or “sleeve” gastrectomy [SG], which is currently the most 
widely performed technique in 47 % of cases); b) purely 
malabsorptive techniques in which distal intestinal diver-
sion is performed (biliopancreatic diversion with duodenal 
switch [BPD-DS]; 1.1 % of cases); and c) mixed techniques 
in which the restrictive and malabsorptive components are 
combined such as Roux-en-Y gastric bypass (RYGBP, 46 % 
of worldwide procedures), biliopancreatic diversion (BPD) 
and one anastomosis gastric bypass or mini-gastric bypass 
(MGB/OAGB). The order of effectiveness for weight loss and 
diabetes improvement is BPD > RYGBP > SGS > AGB. Figu-
res 2 and 3 show the most frequently used techniques (18).
It is worth highlighting that this type of surgery is termed 
bariatric (from “baros” meaning weight) and metabolic sur-
gery. This is due to the fact that, apart from weight loss, an 
early remission of DM-T2 was observed in the first days of 
the postoperative period, both in restrictive and mixed mo-
dels. Years later, the “incretins” and their role in the regu-
lation of energy metabolism were identified such as gluca-
gon-like peptide 1 (GLP-1), glucagon-like peptide-2 (GLP-2), 
glucose-dependent insulinotropic polypeptide (GIP), ghre-
lin (GR) and peptide tyrosine-tyrosine (PYY). Their role in 
the regulation of energy metabolism was also determined, 
thus confirming the metabolic effect of the surgery (7).
Generally speaking, the effects of BMS can be classified into 
three groups: a) those which are independent of the weight 
loss and result from the physiologic consequences of the 
anatomical and physiologic reconfiguration caused by sur-
gery; b) those associated with the weight loss; and c) those 
caused by changes occurring within the adipose tissue (3).
Here we will briefly describe the effect that is independent 
of weight loss and those secondary to the anatomical re-
configuration. These have highlighted the involvement of 
the gastro-entero-insular axis in the regulation of energy 
metabolism and the resolution of comorbidities. Further-
more, these physiologic changes have served as the foun-
dation for endoluminal prototype design (EndoBarrier®, 
Gelesis 100, duodenal mucosal resurfacing) (14,15).
GLUCAGON-LIKE PEPTIDE-1 (GLP-1)
As mentioned previously, one of the most striking effects 
of BMS is the early resolution (during the first days of the 
postoperative period) of DM-T2. Especially with the techni-
ques that exclude duodenal transit (RYGB, biliopancreatic 
diversion with or without duodenal switch and OAGB) or 
those in which the digestive transit is accelerated, as in SG 
(3,16). 
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Fig. 1. Schematic representation of the immunometabolic response in obesity. Obesity leads to the 
induction of infl ammatory signaling pathways. TNF-α: tumor necrosis factor-α; IL-6: interleukin-6; 
TGF-β: transforming growth factor-β; IGF-1: insulin growth factor; DAMPs: damage associated 
molecular patterns.
Fig. 2. The most common bariatric surgical procedures. A. Adjustable gastric banding. B. Sleeve 
gastrectomy. C. Roux-en-Y gastric bypass. Adapted from John L. Cameron and C. Sandone.
Fig. 3. A. Duodenal switch (adapted from John L. Cameron and C. Sandone). B. Mini gastric bypass-
one anastomosis gastric bypass.
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The incretin effect of the surgery is due to the release of 
glucagon-like peptide (GLP-1) and glucose-dependent in-
sulinotropic polypeptide by the EEC of the intestine. The 
rapid arrival of macronutrients to the proximal and distal 
intestine stimulates the secretion of GLP-1 and GIP in ente-
roendocrines K and L cells (19).
GLP-1 has other pleiotropic effects related to DM-T1. It stimu-
lates the secretion of insulin, increases the number and mass 
of pancreatic islets and inhibits apoptosis of B cells. It is worth 
noting that pancreatic functional reserve is the factor that best 
predicts the resolution of DM-T2. Furthermore, it is the basis 
for widening the indications for surgery to obese and predia-
betic patients and for not delaying surgery until the endocrine 
pancreas is “exhausted”, as the outcome would be worse. This 
trend represents a challenge for health systems as limited re-
sources for this population have to be prioritized (3).
It has already been mentioned that the benefits of BMS 
are much greater than diet or life style changes for the re-
solution or control of DM-T2 (75-80 %) (12). In addition to 
the endocrine response of the pancreas, other adjuvant 
mechanisms intervene over the long-term in the resolu-
tion of DM-T2, such as calorie restriction and weight loss 
(3). Other studies have also reported hyperplasia of all the 
layers of the intestinal wall, increase in L cells and an in-
crease in glucose metabolism following RYBP (7). Further-
more, bariatric-metabolic surgery (SG, RYGB and OAGB) 
stimulates the release of anorexigenic hormones such as 
GLP-1, peptide YY and oxyntomodulin. These cause a sen-
sation of early satiety and reduce calorie intake (19).
GHRELIN (GH)
Ghrelin is a 28 aminoacid polypeptide that is synthesized 
in the endocrine cells of the oxyntic glands of the gastric 
fundus. It exerts central (in the hypothalamus) and peri-
pheral effects, stimulating appetite and food intake with 
the subsequent increase in body weight and adipose tis-
sue, and is known as the “hunger hormone” (20).
The effects of a restrictive technique such as gastric ban-
ding on ghrelin levels are controversial. Some studies have 
reported a decrease in ghrelin levels, while most have ob-
served an increase in the levels of this hormone with a pro-
longed follow-up (six months to four years). These changes 
in ghrelin have been linked to weight loss and not to a di-
rect effect of AGB, which could explain the relapses and loss 
of efficacy of AGB in the long term. In contrast, the main 
source of ghrelin is resected (the gastric fundus) in a vertical 
sleeve gastrectomy and a reduction in the baseline and pos-
tprandial levels of ghrelin has been reported (21).
Reported outcomes have been contradictory with regard to 
the effect of RYGBP. These were related to the specific pa-
tient factors (BMI, preoperative severity of the DM-T2) and 
the surgical technique used, such as size and orientation of 
the residual gastric reservoir and the length of the loop (7). 
Our group has reported reductions in ghrelin levels but this 
depended on the exclusion of the fundus and the lack of 
contact of macronutrients with oxyntic cells (21).
PEPTIDE YY (PYY)
Another of the gut hormones involved in the “metabolic” 
effect of bariatric-metabolic surgery is the peptide tyro-
sine-tyrosine (PYY) (22). PYY was first isolated in 1982 
and is synthesized in enteroendocrine L cells and α and 
δ pancreatic cells (22). Two endogenous forms have been 
identified, PYY1-36 and PYY3-36, with different functions. PYY 
levels fall when fasting and increase with food intake, de-
pending on the composition of the macronutrients. It has 
an anorexigenic and regulating effect on energy metabo-
lism. As is the case with other incretins such as GL-P1 and 
BYP-GP, SG leads to an early and lasting PYY release (> 12 
months) of PYY which is associated with the rapid arrival 
of undigested food in the intestine (22).
It is striking that these surgical techniques exert a much 
stronger stimulus on the release of PYY than calorie res-
triction (1,300-1,800 kcal/day) or gastric banding. This ex-
plains why surgery yields better results than dieting or 
physical exercise. Furthermore, it has been reported that 
PYY3-36 exerts a synergistic effect with GL-P1 on insulin se-
cretion, improving glucose tolerance (22). Over the last 
decade, the search for drugs that are PYY agonists has in-
tensified.
CHANGES IN EATING HABITS
Beneficial changes have been reported with regard to food 
intake and food preferences in RYGB. A reduction in food 
intake, an aversion to fats and carbohydrate-rich foods 
and a preference for fruits and vegetables have been re-
ported. In one study, 65 % of patients undergoing RYGP 
experienced a reduced taste for sweet foods, whereas 
62 % of patients undergoing AGB reported an increased 
taste for these foods (23). Overall, 82 % of patients under-
going RYGB and 45 % receiving AGB reported changes in 
taste.
Studies using functional magnetic resonance imaging 
(fMRI) have confirmed that RYGBP induces changes in the 
cerebral circuits related to the “reward” system and the 
mesolimbic pathways related to food addiction. In general, 
RYGBP is more effective than AGB in reducing the intake 
of fats and stimulating the consumption of fruits and ve-
getables. Although at present there are still few studies on 
sleeve gastrectomy, it appears to have the same effect as 
RYGBP (3,7,19).
FOOD INTOLERANCE
Apart from the changes mentioned above, bariatric-meta-
bolic surgery causes a series of symptoms and syndromes 
inherent to the anatomical reconfiguration. These include 
postprandial fullness, nausea, vomiting and dumping syn-
drome, all of which are important in long-term outcomes. 
Patients adapt better over time with the mixed procedures 
(RYGBP, MGBP, OMGB) and with SG than with adjustable 
gastric banding (24).
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ASSESSMENT OF OUTCOMES AND 
FUTURE PROSPECTS
The reported efficacy of BMS should be refined by means 
of the implementation of predictive parameters (to gauge 
response to treatment), which would allow a better identi-
fication and selection of patients for BMS or bariatric en-
doscopy (3). The body mass index does not discriminate 
between different degrees of adiposity, insulin reserve or 
cardiovascular risk factors (10). Currently, there exist me-
thods to evaluate body composition. This allows surgical 
indications to be individualized, outcomes to be asse-
ssed more accurately, and more personalized care to be 
offered based on the physiologic parameters of patients 
with other diseases such as breast and colon cancer (25). 
This also applies to the better identification of the obesity 
phenotypes with metabolically healthy obesity, with com-
parable adverse cardiometabolic profiles to patients with 
metabolically altered obesity (25).
In line with this, some prognostic scales such as the Dia-
rem Score or the Edmonton Obesity Staging System 
(EOSS) have been developed, which allow comorbidities 
and functional status to be evaluated. This “holistic” vision 
of obesity should be incorporated into the practice of both 
gastroenterologists and surgeons, so that better long-term 
results with lower levels of morbidity can be obtained (3).
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